Search

Your search keyword '"Gianni, Alessandro Massimo"' showing total 46 results
Start Over Author "Gianni, Alessandro Massimo"
46 results on '"Gianni, Alessandro Massimo"'

1. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Author

Cavo, Michele, Fanin, Renato, Foa', Roberto, Rambaldi, Alessandro, Di Raimondo, Francesco, Rossi, Giuseppe, Boccadoro, Mario, Leoni, Pietro, Corradini, Paolo, Torelli, Giuseppe, Fioritoni, Giuseppe, Cortelazzo, Sergio, Lambertenghi Deliliers, Giorgio, La Nasa, Giorgio, Zaccaria, Alfonso, De Fabritiis, Paolo, Cascavilla, Nicola, Bosi, Alberto, Semenzato, Gianpietro, Gugliotta, Luigi, Gherlinzoni, Filippo, Angelucci, Emanuele, Martelli, Massimo Fabrizio, Petti, Maria Concetta, Leone, Giuseppe, Carella, Angelo Michele, Ciceri, Fabio, Santoro, Armando, Ferrara, Felicetto, Nobile, Francesco, D'Arco, Alfonso Maria, Levis, Alessandro, Guardigni, Luciano, Gallamini, Andrea, Musto, Pellegrino, Fattori, Pier Paolo, Galieni, Piero, Morandi, Sergio, Amadori, Dino, Gobbi, Marco, Rotoli, Bruno, Mirto, Salvatore, Lazzaro, Antonio, Paladini, Giorgio, Mozzana, Ruggero, Pinotti, Graziella, Rodeghiero, Francesco, Cantore, Nicola, Pavone, Vincenzo, Pogliani, Enrico Maria, Liberati, Anna Marina, Majolino, Ignazio, Amadori, Sergio, Lauria, Francesco, Aglietta, Massimo, Quarta, Giovanni, Storti, Sergio, Morabito, Fortunato, Capalbo, Silvana Franca, Gianni, Alessandro Massimo, Mettivier, Vincenzo, Rizzoli, Vittorio, Bernasconi, Carlo, Visani, Giuseppe, Pizzuti, Michele, La Verde, Giacinto, Avvisati, Giuseppe, Longinotti, Maurizio, Gallo, Eugenio, Dammacco, Franco, Russo, Domenico, Bacigalupo, Andrea, Musolino, Caterina, Tacchetti, Paola, Pantani, Lucia, Patriarca, Francesca, Petrucci, Maria Teresa, Zamagni, Elena, Dozza, Luca, Galli, Monica, Crippa, Claudia, Barbato, Simona, Tosi, Patrizia, Narni, Franco, Montefusco, Vittorio, Testoni, Nicoletta, Spadano, Antonio, Terragna, Carolina, Pescosta, Norbert, Marzocchi, Giulia, Cellini, Claudia, Ronconi, Sonia, Catalano, Lucio, De Sabbata, Giovanni, Cangialosi, Clotilde, Ciambelli, Fabrizio, and Elice, Francesca

Published
2020
Full Text
View/download PDF

2. Supplementary Materials and Methods from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site

Author

Rivoltini, Licia, primary, Chiodoni, Claudia, primary, Squarcina, Paola, primary, Tortoreto, Monica, primary, Villa, Antonello, primary, Vergani, Barbara, primary, Bürdek, Maja, primary, Botti, Laura, primary, Arioli, Ivano, primary, Cova, Agata, primary, Mauri, Giorgio, primary, Vergani, Elisabetta, primary, Bianchi, Beatrice, primary, Della Mina, Pamela, primary, Cantone, Laura, primary, Bollati, Valentina, primary, Zaffaroni, Nadia, primary, Gianni, Alessandro Massimo, primary, Colombo, Mario Paolo, primary, and Huber, Veronica, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure S2 from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site

Author

Rivoltini, Licia, primary, Chiodoni, Claudia, primary, Squarcina, Paola, primary, Tortoreto, Monica, primary, Villa, Antonello, primary, Vergani, Barbara, primary, Bürdek, Maja, primary, Botti, Laura, primary, Arioli, Ivano, primary, Cova, Agata, primary, Mauri, Giorgio, primary, Vergani, Elisabetta, primary, Bianchi, Beatrice, primary, Della Mina, Pamela, primary, Cantone, Laura, primary, Bollati, Valentina, primary, Zaffaroni, Nadia, primary, Gianni, Alessandro Massimo, primary, Colombo, Mario Paolo, primary, and Huber, Veronica, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure Legends from TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site

Author

Rivoltini, Licia, primary, Chiodoni, Claudia, primary, Squarcina, Paola, primary, Tortoreto, Monica, primary, Villa, Antonello, primary, Vergani, Barbara, primary, Bürdek, Maja, primary, Botti, Laura, primary, Arioli, Ivano, primary, Cova, Agata, primary, Mauri, Giorgio, primary, Vergani, Elisabetta, primary, Bianchi, Beatrice, primary, Della Mina, Pamela, primary, Cantone, Laura, primary, Bollati, Valentina, primary, Zaffaroni, Nadia, primary, Gianni, Alessandro Massimo, primary, Colombo, Mario Paolo, primary, and Huber, Veronica, primary

Published
2023
Full Text
View/download PDF

5. Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry

Author

Pedrazzoli, Paolo, Martinelli, Giovanni, Gianni, Alessandro Massimo, Da Prada, Gian Antonio, Ballestrero, Alberto, Rosti, Giovanni, Frassineti, Giovanni Luca, Aieta, Michele, Secondino, Simona, Cinieri, Saverio, Fedele, Roberta, Bengala, Carmelo, Bregni, Marco, Grasso, Donatella, De Giorgi, Ugo, Lanza, Francesco, Castagna, Luca, Bruno, Barbara, and Martino, Massimo

Published
2014
Full Text
View/download PDF

6. A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma

Author

Derenzini, Enrico, Mazzara, Saveria, Melle, Federica, Motta, Giovanna, Fabbri, Marco, Bruna, Riccardo, Agostinelli, Claudio, Cesano, Alessandra, Corsini, Chiara Antonia, Chen, Ning, Righi, Simona, Sabattini, Elena, Chiappella, Annalisa, Calleri, Angelica, Fiori, Stefano, Tabanelli, Valentina, Cabras, Antonello, Pruneri, Giancarlo, Vitolo, Umberto, Gianni, Alessandro Massimo, Rambaldi, Alessandro, Corradini, Paolo, Zinzani, Pier Luigi, Tarella, Corrado, and Pileri, Stefano

Subjects
Proto-Oncogene Proteins c-myc, NF-KappaB Inhibitor alpha, Proto-Oncogene Proteins c-bcl-2, Gene Expression Profiling, Antineoplastic Combined Chemotherapy Protocols, Proto-Oncogene Proteins c-bcl-6, Humans, Lymphoma, Large B-Cell, Diffuse, Prognosis, Risk Assessment, Article
Abstract

Recent randomized trials focused on gene expression-based determination of the cell of origin in diffuse large B-cell lymphoma could not show significant improvements by adding novel agents to standard chemoimmunotherapy. The aim of this study was the identification of a gene signature able to refine current prognostication algorithms and applicable to clinical practice. Here we used a targeted gene expression profiling panel combining the Lymph2Cx signature for cell of origin classification with additional targets including MYC, BCL-2 and NFKBIA, in 186 patients from two randomized trials (discovery cohort) (clinicaltrials gov. Identifier: NCT00355199 and NCT00499018). Data were validated in three independent series (two large public datasets and a real-life cohort). By integrating the cell of origin, MYC/BCL-2 double expressor status and NFKBIA expression, we defined a three-gene signature combining MYC, BCL-2 and NFKBIA (MBN-signature), which outperformed the MYC/BCL-2 double expressor status in multivariate analysis, and allowed further risk stratification within the germinal center B-cell/unclassified subset. The high-risk (MBN Sig-high) subgroup identified the vast majority of double hit cases and a significant fraction of activated B-cell-derived diffuse large B-cell lymphomas. These results were validated in three independent series including a cohort from the REMoDL-B trial, where, in an exploratory ad hoc analysis, the addition of bortezomib in the MBN Sig-high subgroup provided a progression free survival advantage compared with standard chemoimmunotherapy. These data indicate that a simple three-gene signature based on MYC, BCL-2 and NFKBIA could refine the prognostic stratification in diffuse large B-cell lymphoma, and might be the basis for future precision-therapy approaches.

Published
2020

8. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)

Author

Mian, Michael, Marcheselli, Luigi, Luminari, Stefano, Federico, Massimo, Cantonetti, Maria, Sarris, Andreas H., Rossi, Andrea, Rambaldi, Alessandro, Frontani, Marina, Devizzi, Liliana, Gianni, Alessandro Massimo, Busetto, Mario, Berti, Emilio, Martinelli, Giovanni, Tsang, Richard W., Ferreri, Andrés J. M., Pinotti, Graziella, Pogliani, Enrico, Zucca, Emanuele, and Cortelazzo, Sergio

Published
2011
Full Text
View/download PDF

11. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Author

Tacchetti, Paola, primary, Pantani, Lucia, additional, Patriarca, Francesca, additional, Petrucci, Maria Teresa, additional, Zamagni, Elena, additional, Dozza, Luca, additional, Galli, Monica, additional, Di Raimondo, Francesco, additional, Crippa, Claudia, additional, Boccadoro, Mario, additional, Barbato, Simona, additional, Tosi, Patrizia, additional, Narni, Franco, additional, Montefusco, Vittorio, additional, Testoni, Nicoletta, additional, Spadano, Antonio, additional, Terragna, Carolina, additional, Pescosta, Norbert, additional, Marzocchi, Giulia, additional, Cellini, Claudia, additional, Galieni, Piero, additional, Ronconi, Sonia, additional, Gobbi, Marco, additional, Catalano, Lucio, additional, Lazzaro, Antonio, additional, De Sabbata, Giovanni, additional, Cangialosi, Clotilde, additional, Ciambelli, Fabrizio, additional, Musto, Pellegrino, additional, Elice, Francesca, additional, Cavo, Michele, additional, Fanin, Renato, additional, Foa', Roberto, additional, Rambaldi, Alessandro, additional, Rossi, Giuseppe, additional, Leoni, Pietro, additional, Corradini, Paolo, additional, Torelli, Giuseppe, additional, Fioritoni, Giuseppe, additional, Cortelazzo, Sergio, additional, Lambertenghi Deliliers, Giorgio, additional, La Nasa, Giorgio, additional, Zaccaria, Alfonso, additional, De Fabritiis, Paolo, additional, Cascavilla, Nicola, additional, Bosi, Alberto, additional, Semenzato, Gianpietro, additional, Gugliotta, Luigi, additional, Gherlinzoni, Filippo, additional, Angelucci, Emanuele, additional, Martelli, Massimo Fabrizio, additional, Petti, Maria Concetta, additional, Leone, Giuseppe, additional, Carella, Angelo Michele, additional, Ciceri, Fabio, additional, Santoro, Armando, additional, Ferrara, Felicetto, additional, Nobile, Francesco, additional, D'Arco, Alfonso Maria, additional, Levis, Alessandro, additional, Guardigni, Luciano, additional, Gallamini, Andrea, additional, Fattori, Pier Paolo, additional, Morandi, Sergio, additional, Amadori, Dino, additional, Rotoli, Bruno, additional, Mirto, Salvatore, additional, Paladini, Giorgio, additional, Mozzana, Ruggero, additional, Pinotti, Graziella, additional, Rodeghiero, Francesco, additional, Cantore, Nicola, additional, Pavone, Vincenzo, additional, Pogliani, Enrico Maria, additional, Liberati, Anna Marina, additional, Majolino, Ignazio, additional, Amadori, Sergio, additional, Lauria, Francesco, additional, Aglietta, Massimo, additional, Quarta, Giovanni, additional, Storti, Sergio, additional, Morabito, Fortunato, additional, Capalbo, Silvana Franca, additional, Gianni, Alessandro Massimo, additional, Mettivier, Vincenzo, additional, Rizzoli, Vittorio, additional, Bernasconi, Carlo, additional, Visani, Giuseppe, additional, Pizzuti, Michele, additional, La Verde, Giacinto, additional, Avvisati, Giuseppe, additional, Longinotti, Maurizio, additional, Gallo, Eugenio, additional, Dammacco, Franco, additional, Russo, Domenico, additional, Bacigalupo, Andrea, additional, and Musolino, Caterina, additional

Published
2020
Full Text
View/download PDF

12. Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody

Author

Martini, Silvia, primary, Figini, Mariangela, additional, Croce, Aurora, additional, Frigerio, Barbara, additional, Pennati, Marzia, additional, Gianni, Alessandro Massimo, additional, De Marco, Cinzia, additional, Daidone, Maria Grazia, additional, Argueta, Christian, additional, Landesman, Yosef, additional, Zaffaroni, Nadia, additional, and Satta, Alessandro, additional

Published
2020
Full Text
View/download PDF

13. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses

Author

Gallamini, Andrea, Patti, Caterina, Viviani, Simonetta, Rossi, Andrea, Fiore, Francesca, Di Raimondo, Francesco, Cantonetti, Maria, Stelitano, Caterina, Feldman, Tatyana, Gavarotti, Paolo, Sorasio, Roberto, Mulè, Antonino, Leone, Monica, Rambaldi, Alessandro, Biggi, Alberto, Barrington, Sally, Fallanca, Federico, Ficola, Umberto, Chauvie, Stéphane, and Gianni, Alessandro Massimo

Published
2011
Full Text
View/download PDF

14. Early serum TARC reduction predicts prognosis in advanced‐stage Hodgkin lymphoma patients treated with a PET ‐adapted strategy

Author

Viviani, Simonetta, primary, Mazzocchi, Arabella, additional, Pavoni, Chiara, additional, Taverna, Francesca, additional, Rossi, Andrea, additional, Patti, Caterina, additional, Romano, Alessandra, additional, Trentin, Livio, additional, Sorasio, Roberto, additional, Guidetti, Anna, additional, Gottardi, Daniela, additional, Tarella, Corrado, additional, Cimminiello, Michele, additional, Zanotti, Roberta, additional, Farina, Lucia, additional, Ferreri, Andrés José Maria, additional, Galbiati, Marina, additional, Corradini, Paolo, additional, Gianni, Alessandro Massimo, additional, Gallamini, Andrea, additional, and Rambaldi, Alessandro, additional

Published
2020
Full Text
View/download PDF

15. A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy

Author

Satta, Alessandro, primary, Grazia, Giulia, additional, Caroli, Francesco, additional, Frigerio, Barbara, additional, Di Nicola, Massimo, additional, Raspagliesi, Francesco, additional, Mezzanzanica, Delia, additional, Zaffaroni, Nadia, additional, Gianni, Alessandro Massimo, additional, Anichini, Andrea, additional, and Figini, Mariangela, additional

Published
2019
Full Text
View/download PDF

17. Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

Author

Bruna, Riccardo, primary, Benedetti, Fabio, additional, Boccomini, Carola, additional, Patti, Caterina, additional, Barbui, Anna Maria, additional, Pulsoni, Alessandro, additional, Musso, Maurizio, additional, Liberati, Anna Marina, additional, Gini, Guido, additional, Castellino, Claudia, additional, Rossini, Fausto, additional, Ciceri, Fabio, additional, Rota-Scalabrini, Delia, additional, Stelitano, Caterina, additional, Di Raimondo, Francesco, additional, Tucci, Alessandra, additional, Devizzi, Liliana, additional, Zoli, Valerio, additional, Zallio, Francesco, additional, Narni, Franco, additional, Dondi, Alessandra, additional, Parvis, Guido, additional, Semenzato, Gianpietro, additional, Lanza, Francesco, additional, Perrone, Tommasina, additional, Angrilli, Francesco, additional, Billio, Atto, additional, Gueli, Angela, additional, Mantoan, Barbara, additional, Rambaldi, Alessandro, additional, Gianni, Alessandro Massimo, additional, Corradini, Paolo, additional, Passera, Roberto, additional, Ladetto, Marco, additional, and Tarella, Corrado, additional

Published
2019
Full Text
View/download PDF

19. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells

Author

Satta, Alessandro, primary, Mezzanzanica, Delia, additional, Caroli, Francesco, additional, Frigerio, Barbara, additional, Nicola, Massimo Di, additional, Kontermann, Roland E., additional, Iacovelli, Federico, additional, Desideri, Alessandro, additional, Anichini, Andrea, additional, Canevari, Silvana, additional, Gianni, Alessandro Massimo, additional, and Figini, Mariangela, additional

Published
2018
Full Text
View/download PDF

20. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial

Author

Gallamini, Andrea, primary, Tarella, Corrado, additional, Viviani, Simonetta, additional, Rossi, Andrea, additional, Patti, Caterina, additional, Mulé, Antonino, additional, Picardi, Marco, additional, Romano, Alessandra, additional, Cantonetti, Maria, additional, La Nasa, Giorgio, additional, Trentin, Livio, additional, Bolis, Silvia, additional, Rapezzi, Davide, additional, Battistini, Roberta, additional, Gottardi, Daniela, additional, Gavarotti, Paolo, additional, Corradini, Paolo, additional, Cimminiello, Michele, additional, Schiavotto, Corrado, additional, Parvis, Guido, additional, Zanotti, Roberta, additional, Gini, Guido, additional, Ferreri, Andrés J.M., additional, Viero, Piera, additional, Miglino, Maurizio, additional, Billio, Atto, additional, Avigdor, Abraham, additional, Biggi, Alberto, additional, Fallanca, Federico, additional, Ficola, Umberto, additional, Gregianin, Michele, additional, Chiaravalloti, Agostino, additional, Prosperini, Giuseppe, additional, Bergesio, Fabrizio, additional, Chauvie, Stephane, additional, Pavoni, Chiara, additional, Gianni, Alessandro Massimo, additional, and Rambaldi, Alessandro, additional

Published
2018
Full Text
View/download PDF

21. Updated 13 Yr Follow-Up of the GITMO-IIL Trial Comparing Upfront R-HDS with Autograft vs. CHOP-R in High-Risk Follicular Lymphoma: Prolonged Survival in Both Arms and a High Rate of Long-Term Disease Free Survivors

Author

Bruna, Riccardo, primary, Benedetti, Fabio, additional, Boccomini, Carola, additional, Patti, Caterina, additional, Barbui, Anna Maria, additional, Pulsoni, Alessandro, additional, Musso, Maurizio, additional, Liberati, Anna Marina, additional, Gini, Guido, additional, Castellino, Claudia, additional, Rossini, Fausto, additional, Ciceri, Fabio, additional, Rota-Scalabrini, Delia, additional, Stelitano, Caterina, additional, Di Raimondo, Francesco, additional, Tucci, Alessandra, additional, Devizzi, Liliana, additional, Zoli, Valerio, additional, Zallio, Francesco, additional, Narni, Franco, additional, Dondi, Alessandra, additional, Parvis, Guido, additional, Semenzato, Gianpietro, additional, Lanza, Francesco, additional, Perrone, Tommasina, additional, Angrilli, Francesco, additional, Billio, Atto, additional, Gueli, Angela, additional, Mantoan, Barbara, additional, Rambaldi, Alessandro, additional, Gianni, Alessandro Massimo, additional, Corradini, Paolo, additional, Passera, Roberto, additional, Ladetto, Marco, additional, and Tarella, Corrado, additional

Published
2018
Full Text
View/download PDF

22. Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas

Author

Cortelazzo, Sergio, primary, Tarella, Corrado, additional, Gianni, Alessandro Massimo, additional, Ladetto, Marco, additional, Barbui, Anna Maria, additional, Rossi, Andrea, additional, Gritti, Giuseppe, additional, Corradini, Paolo, additional, Di Nicola, Massimo, additional, Patti, Caterina, additional, Mulé, Antonino, additional, Zanni, Manuela, additional, Zoli, Valerio, additional, Billio, Atto, additional, Piccin, Andrea, additional, Negri, Giovanni, additional, Castellino, Claudia, additional, Di Raimondo, Francesco, additional, Ferreri, Andrés J.M., additional, Benedetti, Fabio, additional, La Nasa, Giorgio, additional, Gini, Guido, additional, Trentin, Livio, additional, Frezzato, Maurizio, additional, Flenghi, Leonardo, additional, Falorio, Simona, additional, Chilosi, Marco, additional, Bruna, Riccardo, additional, Tabanelli, Valentina, additional, Pileri, Stefano, additional, Masciulli, Arianna, additional, Delaini, Federica, additional, Boschini, Cristina, additional, and Rambaldi, Alessandro, additional

Published
2016
Full Text
View/download PDF

23. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry

Author

Pedrazzoli, Paolo, Martinelli, Giovanni, Gianni, Alessandro Massimo, Da Prada, Gian Antonio, Ballestrero, Alberto, Rosti, Giovanni, Frassineti, Giovanni Luca, Aieta, Michele, Secondino, Simona, Cinieri, Saverio, Fedele, Roberta, Bengala, Carmelo, Bregni, Marco, Grasso, Donatella, De Giorgi, Ugo, Lanza, Francesco, Castagna, Luca, Bruno, Barbara, Martino, Massimo, and Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule staminali emopoietiche e terapia cellulare

Subjects
NO
Published
2014

24. TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site

Author

Rivoltini, Licia, primary, Chiodoni, Claudia, additional, Squarcina, Paola, additional, Tortoreto, Monica, additional, Villa, Antonello, additional, Vergani, Barbara, additional, Bürdek, Maja, additional, Botti, Laura, additional, Arioli, Ivano, additional, Cova, Agata, additional, Mauri, Giorgio, additional, Vergani, Elisabetta, additional, Bianchi, Beatrice, additional, Della Mina, Pamela, additional, Cantone, Laura, additional, Bollati, Valentina, additional, Zaffaroni, Nadia, additional, Gianni, Alessandro Massimo, additional, Colombo, Mario Paolo, additional, and Huber, Veronica, additional

Published
2016
Full Text
View/download PDF

27. Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients

Author

Guidetti, Anna, primary, Viviani, Simonetta, additional, Dodero, Anna, additional, Farina, Lucia, additional, Russo, Domenico, additional, Bulian, Pietro, additional, Di Nicola, Massimo, additional, Mazzocchi, Arabella, additional, Ravagnani, Fernando, additional, Corradini, Paolo, additional, Gianni, Alessandro Massimo, additional, and Carlo-Stella, Carmelo, additional

Published
2014
Full Text
View/download PDF

29. Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)

Author

Cortelazzo, Sergio, primary, Tarella, Corrado, additional, Gianni, Alessandro Massimo, additional, Barbui, Tiziano, additional, Ladetto, Marco, additional, Barbui, Anna Maria, additional, Rossi, Andrea, additional, Corradini, Paolo, additional, Nicola, Massimo Di, additional, Patti, Caterina, additional, Mulé, Antonino, additional, Zanni, Manuela, additional, Zoli, Valerio, additional, Billio, Atto, additional, Gallamini, Andrea, additional, Raimondo, Francesco Di, additional, Ferreri, Andrés J.M., additional, Pizzolo, Giovanni, additional, La Nasa, Giorgio, additional, Leoni, Pietro, additional, Semenzato, Giampietro, additional, Frezzato, Maurizio, additional, Flenghi, Leonardo, additional, Scarano, Marco, additional, Masciulli, Arianna, additional, Marchioli, Roberto, additional, and Rambaldi, Alessandro, additional

Published
2012
Full Text
View/download PDF

30. HSP105 Inhibition Counteracts Key Oncogenic Pathways and Hampers the Growth of Human Aggressive B-Cell Non-Hodgkin Lymphoma

Author

Zappasodi, Roberta, primary, Cavanè, Alessandra, additional, Tortoreto, Monica, additional, Tringali, Cristina, additional, Ruggiero, Giusi, additional, Castagnoli, Lorenzo, additional, Venerando, Bruno, additional, Zaffaroni, Nadia, additional, Pupa, Serenella M, additional, Gianni, Alessandro Massimo, additional, and Nicola, Massimo Di, additional

Published
2012
Full Text
View/download PDF

31. Abstract LB-433: Biomarker analysis and final results of INT70/09 Phase II proof-of-concept study of Pazopanib (PZP) in refractory urothelial cancer (UC)

Author

Necchi, Andrea, primary, Zaffaroni, Nadia, additional, Mariani, Luigi, additional, Nicolai, Nicola, additional, Crippa, Flavio, additional, Morosi, Carlo, additional, Daidone, Maria Grazia, additional, Gianni, Alessandro Massimo, additional, Braud, Filippo De, additional, and Salvioni, Roberto, additional

Published
2012
Full Text
View/download PDF

32. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)

Author

Mian, Michael, primary, Marcheselli, Luigi, additional, Luminari, Stefano, additional, Federico, Massimo, additional, Cantonetti, Maria, additional, Sarris, Andreas H., additional, Rossi, Andrea, additional, Rambaldi, Alessandro, additional, Frontani, Marina, additional, Devizzi, Liliana, additional, Gianni, Alessandro Massimo, additional, Busetto, Mario, additional, Berti, Emilio, additional, Martinelli, Giovanni, additional, Tsang, Richard W., additional, Ferreri, Andrés J. M., additional, Pinotti, Graziella, additional, Pogliani, Enrico, additional, Zucca, Emanuele, additional, and Cortelazzo, Sergio, additional

Published
2010
Full Text
View/download PDF

34. Dosimetry in Myeloablative 90Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results

Author

Chiesa, Carlo, primary, Botta, Francesca, additional, Di Betta, Erika, additional, Coliva, Angela, additional, Maccauro, Marco, additional, Aliberti, Gianluca, additional, Bavusi, Sergio, additional, Devizzi, Liliana, additional, Guidetti, Anna, additional, Seregni, Ettore, additional, Gianni, Alessandro Massimo, additional, and Bombardieri, Emilio, additional

Published
2007
Full Text
View/download PDF

35. Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Stem Cell Transplantation (SCT) for Relapsed Lymphomas: Impact of Pre-Transplantation Factors on Long-Term Outcome.

Author

Corradini, Paolo, primary, Dodero, Anna, primary, Bregni, Marco, primary, Ciceri, Fabio, primary, Olivieri, Attilio, primary, Farina, Lucia, primary, Valagussa, Pinuccia, primary, Scime’, Rosanna, primary, Locasciulli, Anna, primary, Patriarca, Francesca, primary, Gianni, Alessandro Massimo, primary, and Tarella, Corrado, primary

Published
2005
Full Text
View/download PDF

36. Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation (allo-SCT) Is an Effective Salvage Treatment for Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL).

Author

Corradini, Paolo, primary, Dodero, Anna, primary, Bregni, Marco, primary, Zallio, Francesco, primary, Farina, Lucia, primary, Rambaldi, Alessandro, primary, Patriarca, Francesca, primary, Olivieri, Attilio, primary, Bonifazi, Francesca, primary, Gianni, Alessandro Massimo, primary, and Tarella, Corrado, primary

Published
2005
Full Text
View/download PDF

37. Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease.

Author

Corradini, Paolo, primary, Dodero, Anna, additional, Bregni, Marco, additional, Olivieri, Attilio, additional, Farina, Lucia, additional, Rizzo, Elena, additional, Milani, Raffaella, additional, Scime, Rosanna, additional, Rambaldi, Alessandro, additional, Bonifazi, Francesca, additional, Patriarca, Francesca, additional, Locasciulli, Anna, additional, Bacigalupo, Andrea, additional, Gianni, Alessandro Massimo, additional, and Tarella, Corrado, additional

Published
2004
Full Text
View/download PDF

42. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial

Author

Piera Viero, Simonetta Viviani, Giorgio La Nasa, A. Romano, D. Gottardi, Andrés J.M. Ferreri, Paolo Corradini, Livio Trentin, Alberto Biggi, Federico Fallanca, Maria Cantonetti, G. Gini, Atto Billio, Agostino Chiaravalloti, Giuseppe Prosperini, Davide Rapezzi, A. Mulè, Silvia Bolis, R. Zanotti, Marco Picardi, Chiara Pavoni, Guido Parvis, Corrado Tarella, Paolo Gavarotti, Alessandro Massimo Gianni, Maurizio Miglino, Fabrizio Bergesio, Alessandro Rambaldi, S. Chauvie, Abraham Avigdor, Roberta Battistini, Andrea Gallamini, Michele Gregianin, Andrea Rossi, Corrado Schiavotto, Umberto Ficola, Michele Cimminiello, C. Patti, Gallamini, Andrea, Tarella, Corrado, Viviani, Simonetta, Rossi, Andrea, Patti, Caterina, Mule, Antonino, Picardi, Marco, Romano, Alessandra, Cantonetti, Maria, Nasa, Giorgio La, Trentin, Livio, Bolis, Silvia, Rapezzi, Davide, Battistini, Roberta, Gottardi, Daniela, Gavarotti, Paolo, Corradini, Paolo, Cimminiello, Michele, Schiavotto, Corrado, Parvis, Guido, Zanotti, Roberta, Gini, Guido, Ferreri, Andres J. M., Viero, Piera, Miglino, Maurizio, Billio, Atto, Avigdor, Abraham, Biggi, Alberto, Fallanca, Federico, Ficola, Umberto, Gregianin, Michele, Chiaravalloti, Agostino, Prosperini, Giuseppe, Bergesio, Fabrizio, Chauvie, Stephane, Pavoni, Chiara, Gianni, Alessandro Massimo, and Rambaldi, Alessandro

Subjects
0301 basic medicine, BEACOPP, Male, Cancer Research, medicine.medical_treatment, Procarbazine, 0302 clinical medicine, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, Prospective Studies, Adolescent, Adult, Bleomycin, Cyclophosphamide, Dacarbazine, Doxorubicin, Etoposide, Feasibility Studies, Female, Hodgkin Disease, Humans, Lymph Nodes, Lymphatic Metastasis, Middle Aged, Prednisone, Radiotherapy, Rituximab, Survival Analysis, Vinblastine, Vincristine, Young Adult, Hepatobiliary disease, Oncology, 030220 oncology & carcinogenesis, Radiology, medicine.drug, medicine.medical_specialty, 03 medical and health sciences, medicine, Progression-free survival, business.industry, Settore MED/15, Interim FDG-PET, 030104 developmental biology, ABVD, business, Hodgkin lymphoma
Abstract

Purpose To investigate the progression-free survival (PFS) of patients with advanced Hodgkin lymphoma (HL) after a risk-adapted treatment strategy that was based on a positive positron emission tomography scan performed after two doxorubicin, vinblastine, vincristine, and dacarbazine (ABVD) cycles (PET2). Patients and Methods Patients with advanced-stage (IIB to IVB) HL were consecutively enrolled. After two ABVD cycles, PET2 was performed and centrally reviewed according to the Deauville five-point scale. Patients with a positive PET2 were randomly assigned to four cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) followed by four cycles of standard BEACOPP with or without rituximab. Patients with a negative PET2 continued ABVD, and those with a large nodal mass at diagnosis (≥ 5 cm) in complete remission with a negative PET at the end of chemotherapy were randomly assigned to radiotherapy or no further treatment. The primary end point was 3-year PFS. Results Of 782 enrolled patients, 150 (19%) had a positive and 630 (81%) a negative PET2. The 3-year PFS of all patients was 82%. The 3-year PFS of those with a positive and negative PET2 was 60% and 87%, respectively ( P < .001). The 3-year PFS of patients with a positive PET2 assigned to BEACOPP with or without rituximab was 63% versus 57% ( P = .53). In 296 patients with both interim and post-ABVD–negative PET who had a large nodal mass at diagnosis, radiotherapy was randomly added after chemotherapy without a significant PFS improvement (97% v 93%, respectively; P = .29). The 3-year overall survival of all 782 patients was 97% (99% and 89% for PET2 negative and positive, respectively). Conclusion The PET-driven switch from ABVD to escalated BEACOPP is feasible and effective in high-risk patients with advanced-stage HL.

Published
2018

43. A three-gene signature based on MYC , BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma.

Author

Derenzini E, Mazzara S, Melle F, Motta G, Fabbri M, Bruna R, Agostinelli C, Cesano A, Corsini CA, Chen N, Righi S, Sabattini E, Chiappella A, Calleri A, Fiori S, Tabanelli V, Cabras A, Pruneri G, Vitolo U, Gianni AM, Rambaldi A, Corradini P, Zinzani PL, Tarella C, and Pileri S

Subjects
Gene Expression Profiling, Humans, NF-KappaB Inhibitor alpha, Prognosis, Proto-Oncogene Proteins c-bcl-2 genetics, Proto-Oncogene Proteins c-bcl-6 genetics, Proto-Oncogene Proteins c-myc genetics, Risk Assessment, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse genetics
Abstract

Recent randomized trials focused on gene expression-based determination of the cell of origin in diffuse large B-cell lymphoma could not show significant improvements by adding novel agents to standard chemoimmunotherapy. The aim of this study was the identification of a gene signature able to refine current prognostication algorithms and applicable to clinical practice. Here we used a targeted gene expression profiling panel combining the Lymph2Cx signature for cell of origin classification with additional targets including MYC, BCL-2 and NFKBIA, in 186 patients from 2 randomized trials (discovery cohort) (NCT00355199 and NCT00499018). Data were validated in 3 independent series (2 large public datasets and a real-life cohort). By integrating the cell of origin, MYC/BCL-2 double expressor status and NFKBIA expression, we defined a 3-gene signature combining MYC, BCL-2 and NFKBIA (MBN-signature), which outperformed the MYC/BCL-2 double expressor status in multivariate analysis, and allowed further risk stratification within the germinal center B-cell/unclassified subset. The high-risk (MBN Sig-high) subgroup identified the vast majority of double hit cases and a significant fraction of Activated B-Cell-derived diffuse large B-cell lymphomas. These results were validated in 3 independent series including a cohort from the REMoDL-B trial, where, in an exploratory ad hoc analysis, the addition of bortezomib in the MBN Sig-high subgroup provided a progression free survival advantage compared with standard chemoimmunotherapy. These data indicate that a simple 3-gene signature based on MYC, BCL-2 and NFKBIA could refine the prognostic stratification in diffuse large B-cell lymphoma, and might be the basis for future precision-therapy approaches.

Published
2021
Full Text
View/download PDF

44. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.

Author

Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, and Merlini G

Subjects
Adult, Aged, Amyloidosis mortality, Female, Follow-Up Studies, Humans, Male, Middle Aged, Risk Factors, Survival Analysis, Time, Transplantation, Autologous, Amyloidosis drug therapy, Amyloidosis surgery, Melphalan therapeutic use, Peripheral Blood Stem Cell Transplantation methods, Transplantation Conditioning methods
Abstract

Background and Objectives: High-dose melphalan with autologous peripheral blood stem cell transplantation (ASCT) is an effective treatment for systemic primary amyloidosis. This procedure is, however, associated with substantial toxicity and mortality, particularly if the heart is involved. Refined selection of patients suitable for transplantation and personalized adaptation of the doses of melphalan might improve the outcome., Design and Methods: Twenty-two consecutive patients were selected for age, number of organ systems involved, heart and kidney function, and treated with risk-adapted melphalan conditioning. This was first-line therapy in 81% of cases., Results: Fifty-five percent of the patients had amyloid involvement of two organ systems, with renal involvement predominant in half. Approximately 70% received full-dose melphalan. Toxicity was manageable and three transplant-related deaths (14%) occurred only in the early phase of the study. The median overall survival was 68 months. The intent-to-treat hematologic response rate was 55% at +12 months (complete, 36%; partial, 19%), which was accompanied by organ responses in 75%. Survival was positively influenced by: (i) hematologic response at +3 months (complete+partial responses 55%, median not reached, more than 108 months; no response, median 17 months) (p=0.001); (ii) amyloid involvement of a single organ system (p=0.016). Prolonged follow-up demonstrated that remissions are durable, but relapses may occur as 4 of 12 responsive patients (33%) relapsed, three from complete response, between +30 to +38 months., Interpretation and Conclusions: The present risk-adapted approach produced acceptable toxicity and peri-transplant mortality with prolonged survival in responsive patients. Additional therapy should be considered if no hematologic response is observed at +3 months after ASCT.

Published
2006

45. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside.

Author

Matteucci P, Carlo-Stella C, Di Nicola M, Magni M, Guidetti A, Marchesi M, and Gianni AM

Subjects
Administration, Topical, Adult, Aged, Anti-Inflammatory Agents administration & dosage, Conjunctivitis chemically induced, Conjunctivitis drug therapy, Diclofenac administration & dosage, Female, Humans, Male, Middle Aged, Conjunctivitis prevention & control, Cytarabine adverse effects, Dexamethasone administration & dosage, Premedication
Abstract

We investigated the efficacy of dexamethasone plus diclofenac eye drops as prophylaxis for conjunctivitis induced by high-dose (HD) cytarabine (Ara-C). Sixty patients were randomized to receive either dexamethasone (group A, n=29) or dexamethasone plus diclofenac (group B, n=31). Conjunctivitis was experienced by 13/29 (45%) patients in group A, and 4/31 (13%) patients in group B (p

Published
2006

46. Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma.

Author

Ruffini PA, Di Nicola M, Carlo-Stella C, Siena S, and Gianni AM

Subjects
Animals, Bystander Effect, Cancer Vaccines immunology, Clinical Trials as Topic, Disease Models, Animal, Genetic Vectors, Humans, Immunoglobulin Idiotypes immunology, Lymphoma, Non-Hodgkin immunology, Mice, Models, Immunological, Vaccines, DNA therapeutic use, Cancer Vaccines therapeutic use, Immunoglobulin Idiotypes therapeutic use, Lymphoma, Non-Hodgkin therapy
Abstract

B cell malignancies express a clear tumor-specific antigen (B cell immunoglobulin variable regions) known as idiotype (Id). It is now possible to immunize patients against autologous Id generating humoral and cellular immune responses that correlate with clinical and molecular remissions and the possibility of improved disease-free survival. In its present form, however, individual vaccine preparation by generating heterohybridomas is a technical and financial challenge. DNA vaccination provides a unique opportunity to streamline individual vaccine manufacture by circumventing the need for protein purification. DNA fusion vaccines have been developed in which genetic carriers promote adaptive immunity against the attached Id. Such carriers can specifically bind receptors on dendritic cells (DC) for targeted antigen delivery, or supply high levels of T cell help. Ideally, the carrier should be able to activate innate immunity to enhance the antigen-presenting capacity of DC. The correlates of immunity may vary depending upon the genetic carrier used. Translation to patients has begun with preliminary evidence of Id-specific immune responses. An alternative vaccination strategy that allows for the potential to vaccinate against multiple tumor antigens without the need to identify individual antigens is based on tumor cells themselves to be used as vaccine. To this purpose, however, each patient's tumor cells must be genetically modified to increase their immunogenicity. To overcome the technical limitations inherent with a fully autologous approach, strategies have been devised where a universal, genetically modified bystander cells is expected to provide the immunoenhancing cytokines to allow immune recognition of unmodified patients' tumor cells.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results